Stephenson is currently vice president of Global Market Access and Value at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), where she has served since 2008. Prior to that, she spent 10 years at Pfizer Inc (NYSE:PFE) in various capacities.
“Zynerba is in an important phase of its journey as it begins its preparations for a potential launch of the first product ever indicated for use in children and adolescents with Fragile X Syndrome,” said Stephenson in a statement. “I am excited to join Zynerba’s board of directors at this time, and look forward to contributing to the company’s future successes.”
The Devon, Pennsylvania, company develops transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, including Fragile X Syndrome – a genetic cause of intellectual disability -- and Autism Spectrum Disorder.
“Pamela brings with her a wealth of expertise in commercial planning, market development, product launch and market access,” said Zynerba CEO Armando Anido. “This experience will be essential as we develop the market for ZYN002 in Fragile X Syndrome and await data from our ongoing pivotal CONNECT-FX study.”
Zynerba shares closed at $5.03 Tuesday.
Contact Paul Curcio at [email protected]
Follow him on Twitter @GoCurcioGo